A Phase I/II Study of HE3235 in Patients With Prostate Cancer
Status:
Completed
Trial end date:
2011-03-01
Target enrollment:
Participant gender:
Summary
This is a phase I/II, open-label, dose escalation study of HE3235 administered orally to
patients with advanced prostate cancer who have failed hormone therapy and at least one
taxane based chemotherapy regimen.